XML 34 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Other Expense (Income)
6 Months Ended
Jun. 30, 2020
Other Income and Expenses [Abstract]  
Other Expense (Income) Other Expense (Income)
Other expense (income) consists of:

Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions)2020201920202019
Restructuring and related charges:
Severance and post-employment benefits$—  $1.3  $—  $1.6  
Other charges—  0.1  —  0.4  
Total restructuring and related charges—  1.4  —  2.0  
Fixed asset impairments6.3  1.2  6.5  1.6  
Development and licensing income(0.2) (0.2) (0.4) (0.4) 
Contingent consideration0.1  0.1  0.1  0.3  
Foreign exchange transaction gains(2.0) (4.8) (5.5) (8.6) 
Other items(1.2) (0.2) (1.2) 0.3  
Total other expense (income)$3.0  $(2.5) $(0.5) $(4.8) 

Restructuring and Related Charges

In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was expected to require restructuring and related charges of approximately $16 million. Since its approval, we have recorded $13.7 million in restructuring and related charges associated with this plan. The plan was considered complete as of December 31, 2019.

During the three months ended June 30, 2019, we recorded $1.4 million in restructuring and related charges associated with this plan, consisting of $1.3 million for severance charges, $0.1 million for non-cash asset write-downs associated with the discontinued use of certain equipment.

During the six months ended June 30, 2019, we recorded $2.0 million in restructuring and related charges associated with this plan, consisting of $1.6 million for severance charges, $0.4 million for other charges.

The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

($ in millions)Severance
and benefits
Asset-related chargesOther chargesTotal
Balance, December 31, 2019$1.4  $—  $—  $1.4  
Cash payments(1.0) —  —  (1.0) 
Balance, June 30, 2020$0.4  $—  $—  $0.4  

On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. As of June 30, 2020, we completed our remaining restructuring obligations related to the 2016 restructuring plan.
Other Items

During both the three and six months ended June 30, 2020 and 2019, we recorded development income of $0.2 million and $0.4 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. Please refer to Note 3, Revenue, for additional information.

Contingent consideration represents changes in the fair value of the SmartDose contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.
Other items consist of gains and losses on the sale of fixed assets and miscellaneous income and charges.